Context-Aware Saliency Guided Radiomics: Application to Prediction of Outcome and HPV-Status from Multi-Center PET/CT Images of Head and Neck Cancer.
HPV
PET/CT
head and neck cancer
outcome
radiomics
saliency
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
18
02
2022
revised:
19
03
2022
accepted:
21
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
This multi-center study aims to investigate the prognostic value of context-aware saliency-guided radiomics in 806 HNC patients (training vs. validation vs. external testing: 500 vs. 97 vs. 209) from 9 centers were collected from The Cancer Imaging Archive (TCIA). There were 100/384 and 60/123 oropharyngeal carcinoma (OPC) patients with human papillomavirus (HPV) status in training and testing cohorts, respectively. Six types of images were used for radiomics feature extraction and further model construction, namely (i) the original image (Origin), (ii) a context-aware saliency map (SalMap), (iii, iv) high- or low-saliency regions in the original image (highSal or lowSal), (v) a saliency-weighted image (SalxImg), and finally, (vi) a fused PET-CT image (FusedImg). Four outcomes were evaluated, i.e., recurrence-free survival (RFS), metastasis-free survival (MFS), overall survival (OS), and disease-free survival (DFS), respectively. Multivariate Cox analysis and logistic regression were adopted to construct radiomics scores for the prediction of outcome (Rad_Ocm) and HPV-status (Rad_HPV), respectively. Besides, the prognostic value of their integration (Rad_Ocm_HPV) was also investigated. In the external testing cohort, compared with the Origin model, SalMap and SalxImg achieved the highest C-indices for RFS (0.621 vs. 0.559) and MFS (0.785 vs. 0.739) predictions, respectively, while FusedImg performed the best for both OS (0.685 vs. 0.659) and DFS (0.641 vs. 0.582) predictions. In the OPC HPV testing cohort, FusedImg showed higher AUC for HPV-status prediction compared with the Origin model (0.653 vs. 0.484). In the OPC testing cohort, compared with Rad_Ocm or Rad_HPV alone, Rad_Ocm_HPV performed the best for OS and DFS predictions with C-indices of 0.702 ( Saliency-guided radiomics showed enhanced performance for both outcome and HPV-status predictions relative to conventional radiomics. The radiomics-predicted HPV status also showed complementary prognostic value.
Identifiants
pubmed: 35406449
pii: cancers14071674
doi: 10.3390/cancers14071674
pmc: PMC8996849
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Natural Science Foundation of China
ID : 81871437
Organisme : National Natural Science Foundation of China
ID : 12026601
Organisme : Guangdong Basic and Applied Basic Research Foundation
ID : 2019A1515011104
Organisme : Guangdong Basic and Applied Basic Research Foundation
ID : 2020A1515110683
Organisme : Guangdong Basic and Applied Basic Research Foundation
ID : 2021A1515011676
Organisme : China Postdoctoral Science Foundation
ID : 2020M682792
Références
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):613-22
pubmed: 25573630
Radiol Artif Intell. 2020 Nov 04;2(6):e190218
pubmed: 33937845
Front Cell Dev Biol. 2019 Apr 09;7:52
pubmed: 31024913
Mol Imaging Biol. 2019 Oct;21(5):954-964
pubmed: 30671740
Cancer Treat Rev. 2021 Sep;99:102263
pubmed: 34343892
EBioMedicine. 2019 Jul;45:70-80
pubmed: 31255659
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2638-2655
pubmed: 31240330
Radiographics. 2012 Sep-Oct;32(5):1261-82; discussion 1282-4
pubmed: 22977017
Front Oncol. 2020 Dec 08;10:578895
pubmed: 33364192
J Nucl Med. 2022 Feb;63(2):172-179
pubmed: 34531263
Cancers Head Neck. 2020 May 4;5:6
pubmed: 32391171
IEEE J Biomed Health Inform. 2020 Aug;24(8):2268-2277
pubmed: 31804945
Ann Oncol. 2019 Feb 1;30(2):297-302
pubmed: 30481287
J Nucl Med. 2022 Apr;63(4):500-510
pubmed: 34740952
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Nat Rev Neurosci. 2001 Mar;2(3):194-203
pubmed: 11256080
Lancet. 2021 Dec 18;398(10318):2289-2299
pubmed: 34562395
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1504-1512
pubmed: 27212196
Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1673-84
pubmed: 22854984
Phys Med Biol. 2021 Oct 14;66(20):
pubmed: 34544053
Phys Med Biol. 2021 Dec 07;66(24):
pubmed: 34781280
World J Otorhinolaryngol Head Neck Surg. 2016 Jun;2(2):60-67
pubmed: 28642939
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Radiology. 2019 Apr;291(1):53-59
pubmed: 30694160
J Digit Imaging. 2021 Oct;34(5):1156-1170
pubmed: 34545475
Mol Imaging Biol. 2020 Oct;22(5):1414-1426
pubmed: 31659574
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Biochemistry (Mosc). 2013 Nov;78(11):1201-15
pubmed: 24460935
Cancers (Basel). 2022 Jan 23;14(3):
pubmed: 35158831
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Dent J (Basel). 2019 Sep 04;7(3):
pubmed: 31487927
Crit Rev Oncol Hematol. 2017 May;113:151-155
pubmed: 28427504
Neural Netw. 2006 Nov;19(9):1395-407
pubmed: 17098563
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1117-1142
pubmed: 30064704
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):2978-2991
pubmed: 32399621
IEEE Trans Pattern Anal Mach Intell. 2012 Oct;34(10):1915-26
pubmed: 22201056
Sci Rep. 2020 Jun 24;10(1):10248
pubmed: 32581221
Nat Rev Clin Oncol. 2019 Apr;16(4):241-255
pubmed: 30479378
Tomography. 2020 Jun;6(2):118-128
pubmed: 32548288
Phys Med Biol. 2020 Dec 17;65(24):24TR02
pubmed: 32688357
J Nucl Med. 2018 Aug;59(8):1321-1328
pubmed: 29301932